Dr. Erik Ingelsson, MD, PhD — Chief Scientific Officer of Wave Life Sciences.
For decades we’ve measured obesity using one simple number on a scale — but what if that’s the wrong metric? Today, one of the world’s leading experts in genetics explains why the future of obesity medicine may not be about losing more weight, but about losing the right kind of fat while preserving the muscle that keeps us healthy.
Dr. Erik Ingelsson, MD, PhD is a physician-scientist and internationally recognized leader in human genetics, genomics, and metabolic disease research. He currently serves as Chief Scientific Officer at Wave Life Sciences (https://wavelifesciences.com/), where he leads the development of next-generation RNA medicines designed to address major unmet medical needs.
Before joining Wave, Dr. Ingelsson served as Senior Vice President and Head of Target Discovery at GSK, where he led large-scale efforts integrating human genetics, functional genomics, computational biology, and molecular science to discover and validate new drug targets across therapeutic areas.
Prior to his transition into industry, Dr. Ingelsson was Professor of Medicine at Stanford University, where his laboratory used human genetics and functional genomics to uncover new biological mechanisms underlying insulin resistance, obesity, metabolic disease, and cardiovascular risk.








